New COPD Drug Available
Dr. Ahmed Farooq
Via: PlexusMD
New COPD Drug Available
AstraZeneca announced that the glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) inhaler is now available.

The FDA approved Bevespi Aerosphere in April 2016. The medication is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or for the relief of acute bronchospasm.

Glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg is a twice-daily, fixed-dose dual bronchodilator combining glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-2 agonist (LABA). The FDA approval was based on the PINNACLE trial program, which demonstrated that the inhaled combination achieved statistically significant improvement in morning pre-dose forced expiratory volume in 1 second (FEV1) at 24 weeks (P<0.001) versus its mono-components and placebo....